Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

Literature DB >> 8787913

Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities.

S Rusconi¹, M Moonis, D P Merrill, P V Pallai, E A Neidhardt, S K Singh, K J Willis, M S Osburne, A T Profy, J C Jenson, M S Hirsch.

Abstract

PIC 024-4 and PRO 2000 are naphthalene sulfonate polymers that bind to CD4 with nanomolar affinity and block binding of gp120. Both have activity against human immunodeficiency virus type 1 in H9 cells, peripheral blood mononuclear cells, and primary monocyte/macrophages, are synergistic with zidovudine, and do not inhibit tetanus toxoid-stimulated T-cell proliferation at anti-human immunodeficiency virus type 1 concentrations.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1996 PMID： 8787913 PMCID： PMC163090

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

Review 1. Antiviral therapy for human immunodeficiency virus infections.

Authors: E De Clercq
Journal: Clin Microbiol Rev Date: 1995-04 Impact factor: 26.132

2. The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors: S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal: Science Date: 1986-07-11 Impact factor: 47.728

3. Measurement of ligand binding to proteins by fluorescence spectroscopy.

Authors: L D Ward
Journal: Methods Enzymol Date: 1985 Impact factor: 1.600

4. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight.

Authors: M Cushman; P L Wang; S H Chang; C Wild; E De Clercq; D Schols; M E Goldman; J A Bowen
Journal: J Med Chem Date: 1991-01 Impact factor: 7.446

5. Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2.

Authors: P Mohan; R Singh; M Baba
Journal: J Med Chem Date: 1991-01 Impact factor: 7.446

6. Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds.

Authors: M Cushman; S Kanamathareddy; E De Clercq; D Schols; M E Goldman; J A Bowen
Journal: J Med Chem Date: 1991-01 Impact factor: 7.446

7. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors: D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal: Nature Date: 1984 Dec 20-1985 Jan 2 Impact factor: 49.962

8. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors: A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal: Nature Date: 1984 Dec 20-1985 Jan 2 Impact factor: 49.962

9. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors: M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal: Science Date: 1984-05-04 Impact factor: 47.728

10. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors: L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal: J Virol Date: 1991-03 Impact factor: 5.103

48 in total

1. Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments.

Authors: F Manetti; F Corelli; N Mongelli; A L Borgia; M Botta
Journal: J Comput Aided Mol Des Date: 2000-05 Impact factor: 3.686

2. Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.

Authors: Onofrio Zirafi; Kyeong-Ae Kim; Nadia R Roan; Silvia F Kluge; Janis A Müller; Shibo Jiang; Benjamin Mayer; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal: Sci Transl Med Date: 2014-11-12 Impact factor: 17.956

Review 3. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors: Jessica L Adams; Angela D M Kashuba
Journal: Best Pract Res Clin Obstet Gynaecol Date: 2012-02-04 Impact factor: 5.237

Review 4. Emerging drug targets for antiretroviral therapy.

Authors: Jacqueline D Reeves; Andrew J Piefer
Journal: Drugs Date: 2005 Impact factor: 9.546

Review 5. Novel targets for antiretroviral therapy: clinical progress to date.

Authors: Birgitt Dau; Mark Holodniy
Journal: Drugs Date: 2009 Impact factor: 9.546

6. Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis.

Authors: Nicola Richardson-Harman; Carol Lackman-Smith; Patricia S Fletcher; Peter A Anton; James W Bremer; Charlene S Dezzutti; Julie Elliott; Jean-Charles Grivel; Patricia Guenthner; Phalguni Gupta; Maureen Jones; Nell S Lurain; Leonid B Margolis; Swarna Mohan; Deena Ratner; Patricia Reichelderfer; Paula Roberts; Robin J Shattock; James E Cummins
Journal: J Clin Microbiol Date: 2009-09-02 Impact factor: 5.948

10. A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection.

Authors: Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Robert F Rando; Mohamed Labib; Fred C Krebs
Journal: J Biomed Biotechnol Date: 2010-05-31